Monoclonal Antibodies Market: Current Analysis and Forecast (2022-2028)

Monoclonal Antibodies Market: Current Analysis and Forecast (2022-2028)

Monoclonal antibodies are laboratory-produced proteins that are used for boosting the immune system. These are utilized for the management of several diseases, including cancer, autoimmune diseases, viral disease treatment, and others. The main advantage of using monoclonal antibodies in treating these diseases are they are taken from a biological source and can produce antibodies in the long term. To date, more than 100 monoclonal antibodies have been granted approval such as Rituximab, Herceptin, Jemperli, and others. The monoclonal antibodies market is growing at a tremendous rate owing to surge in the prevalence of cancer, Alzheimer, Parkinson, and other diseases.

The Monoclonal Antibodies Market is expected to grow at a strong CAGR of 9% during the forecast period owing to the rising pharmaceutical investment for the development of monoclonal antibodies. Pharmaceutical companies have adopted strategic alliances to maintain a competitive edge in the global market. For instance, in March 2023, Simcere Pharmaceutical Group in collaboration with Merck is evaluating the combination of SIM0235, a potential first-in-class humanized anti-tumor necrosis factor receptor 2 (TNFR2) monoclonal antibody, and Keytruda in patients with advanced solid tumors and cutaneous T-cell lymphoma (CTCL).

• Based on source, the market is segmented into chimeric, human, humanized, and murine. The humanized antibodies are anticipated to grow with significant CAGR during the forecast period owing to their widespread use for a wide range of target antigens, such as cancer cells, or immunosuppressor and immunomodulatory molecules. Demand for such antibodies is also supported by their lower immunogenicity as compared to chimeric mAbs.
• By indication, the market is categorized into oncology, autoimmune diseases, infectious diseases, inflammatory diseases, and others. The oncology segment held the dominant share of the market in 2021 owing to rise in the prevalence of cancer. The International Agency for Research on Cancer (IARC), in its report GLOBOCAN, has stated that approximately 19.3 million new cancer cases and about 10 million deaths related to cancer were recorded in 2020, across the globe. The IARC has estimated that new cancer cases are expected to rise by 47% all over the globe from 2020 to 2040. Apart from this, rising product approvals and increasing adoption due to their targeted nature is also having a positive impact on the growth of the segment. For instance, in February 2023, U.S. FDA granted approval to Jemperli for adult patients with mismatch repair–deficient (dMMR), recurrent or advanced endometrial cancer.
• On the basis of end user, the market is segmented into hospital, specialty centers, and others. The specialty centers is anticipated to grow with high CAGR during the forecast period attributed to the rising government support in past few years. For instance, the National Cancer Institute’s Cancer Centers Program is establishing standards for transdisciplinary cancer centers focused on the prevention, diagnosis, and treatment of various types of cancers. Such initiatives are expected to positively affect the segment growth.
• For a better understanding of the market adoption of the Sanger Sequencing Service industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held a significant share of the market in 2021. Several factors such as increasing healthcare expenditure, the surge in the prevalence of chronic diseases, rising patient awareness, and the presence of the majority of key players and their associated surge in research and development activities are driving the regional market. For instance, in February 2022, Eli Lilly and Company announced that U.S. FDA has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant. Bebtelovimab is a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2.
• Some of the major players operating in the market include AbbVie Inc.; F. Hoffmann-La Roche Ltd; Amgen Inc.; Pfizer Inc.; Bristol-Myers Squibb Company; Bayer AG; AstraZeneca; Sanofi; Merck & Co., Inc; and Johnson & Johnson Private Limited.